Annual rank35
Poland · Healthcare
Voxel
Provides imaging diagnostics, teleradiology and radiopharmaceuticals within a group spanning diagnostics, therapeutics and information technology.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Imaging, radiopharmaceuticals and connected care
Voxel combines diagnostic imaging, specialist treatment and healthcare technology in one Polish group. Its clinical businesses perform MRI, CT and PET-CT examinations and remote image interpretation; the group also manufactures short-lived radiopharmaceuticals, operates Gamma Knife services and develops the RIS/PACS infrastructure used to move images and reports through a diagnostic workflow.
Diagnostic network
Acquire an image in one centre and interpret it elsewhere
MRI, CT and PET-CT are the principal examinations in Voxel's diagnostics segment. Teleradiology adds a second layer: images can travel over a secure connection to a specialist in another location, while the same clinical network supports complex imaging protocols and commercial clinical trials.
- Explore the Voxel Group Diagnostics, therapeutics and IT within one operating group
- Diagnostic services MRI, CT, PET-CT, trials and radiopharmaceutical activity
- Clinical-trial capabilities Specialist imaging protocols and research collaboration
Radiopharmaceuticals
Make short-lived tracers close enough to the scanner
Voxel names V-PET, FCH, V-NaF and V-Ga68 in its medicinal-product range. Production sites in Warsaw, Kraków and Katowice support time-critical distribution, while the new 2,505-square-metre Katowice centre combines automated production, clean rooms, microbiology and quality-control laboratories.
- Radiopharmaceutical products and production Named tracers, three production cities and the Katowice centre
- Research and investment context Issuer materials on new radiopharmaceuticals and in-house R&D
- ▶ VideoWatch: inside the new cyclotron facility Language-neutral technical footage of the building and production equipment
Precision therapy
Focus radiation on a target without an open operation
Exira introduced Gamma Knife in Katowice in 2013. Voxel's English technical material explains how multiple cobalt sources focus a high-intensity dose at one point and places the service beside magnetic-resonance imaging, neurosurgery and radiotherapy within the group's therapeutic segment.
- Gamma Knife technical overview English company presentation, including the treatment workflow and Exira
- Leksell Gamma Knife Perfexion The equipment supplier's English product page for the system used by Exira
- GammaPlan The supplier's treatment-planning software for Gamma Knife platforms
- Voxel's three operating segments Current issuer overview of diagnostics, therapeutics and IT
Digital workflow and research
Connect scanners, software and specialist knowledge
Voxel's teleradiology service configures diagnostic equipment, transmission software and data flows for remote reporting. Alteris adds RIS/PACS, turnkey imaging laboratories, telehistopathology and shielded MRI rooms; Voxel's 2022 presentation reported its IT systems in more than 250 hospitals and diagnostic centres.
- Remote reporting workflow Equipment configuration, VPN transmission, training and data flow
- Medical IT deployment English 2022 presentation on RIS/PACS and teleradiology installations
- Alteris product map RIS/PACS, turnkey laboratories, OmniVidi and supporting infrastructure
- Modular and infrastructure projects English presentation showing how Alteris extends beyond software
Official profile sources: Radiopharmaceuticals — Voxel Group · Diagnostics — Voxel Group · Investor Relations — Voxel
Current 2026 update
What has changed in 2026?
Q1 2026 · 28 May 2026
Q1 2026latest official update
3company-specific highlights
0%2026 stock return · context only
Revenue
Q1 sales revenue was broadly flat, edging down to PLN 157.2m from PLN 157.8m.
Operating profit
Q1 operating profit rose to PLN 42.5m from PLN 32.8m.
Profit
Q1 net profit rose to PLN 32.4m from PLN 24.7m.
Official 2026 sources: Selected Financial Data of the Voxel Group for Q1 2026 · 28 May 2026
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 35 | +80% | +147% | +199% |